Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 2/2008

Content (14 Articles)

Original Article

New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen

Wei Li, Heng Cui, Fan-Qiang Meng, Xiao-Hong Chang, Guo Zhang, Bei Liu, Zi-Hai Li

Original Article

Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells

Naofumi Shinagawa, Koichi Yamazaki, Yasuaki Tamura, Akihito Imai, Eiki Kikuchi, Hiroshi Yokouchi, Fumihiro Hommura, Satoshi Oizumi, Masaharu Nishimura

Original Article

Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells

Despina Rudolf, Tobias Silberzahn, Steffen Walter, Dominik Maurer, Johanna Engelhard, Dorothee Wernet, Hans-Jörg Bühring, Gundram Jung, Byoung S. Kwon, Hans-Georg Rammensee, Stefan Stevanović

Original Article

PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting

Nathalie Labarrière, Nadine Gervois, Annabelle Bonnin, Régis Bouquié, Francine Jotereau, François Lang

Open Access Original Article

Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma

Akash M. Mehta, Ekaterina S. Jordanova, Gemma G. Kenter, Soldano Ferrone, Gert- Jan Fleuren

Original Article

Control of lymphocyte infiltration of lung tumors in mice by host’s genes: mapping of four Lynf (lymphocyte infiltration) loci

Neelima Kakarlapudi, Juanita H. J. Vernooy, Lei Quan, Remond J. A. Fijneman, Peter Demant

Original Article

CRMP5 antibodies in patients with small-cell lung cancer or thymoma

Sissel E. Monstad, Lars Drivsholm, Geir Olve Skeie, Jan H. Aarseth, Christian A. Vedeler

Original Article

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein

Julia Stieglmaier, Edwin Bremer, Christian Kellner, Tanja M. Liebig, Bram ten Cate, Matthias Peipp, Hendrik Schulze-Koops, Matthias Pfeiffer, Hans-Jörg Bühring, Johann Greil, Fuat Oduncu, Bertold Emmerich, Georg H. Fey, Wijnand Helfrich

Original Article

Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells

Sophia N. Karagiannis, Marguerite G. Bracher, Rebecca L. Beavil, Andrew J. Beavil, James Hunt, Natalie McCloskey, Richard G. Thompson, Nicholas East, Frances Burke, Brian J. Sutton, David Dombrowicz, Frances R. Balkwill, Hannah J. Gould

Short Communication

Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it?

R. B. Baleeiro, P. C. Bergami-Santos, M. Y. Tomiyoshi, J. L. Gross, F. Haddad, C. A. L. Pinto, F. A. Soares, R. N. Younes, J. A. M. Barbuto

Short Communication

Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer

Helga Bernhard, Julia Neudorfer, Kerstin Gebhard, Heinke Conrad, Christine Hermann, Jörg Nährig, Falko Fend, Wolfgang Weber, Dirk H. Busch, Christian Peschel

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine